Revolution Medicines (RVMD) EBT (2019 - 2026)

Revolution Medicines' EBT history runs 8 years deep, the most recent figure standing at -$453.8 million for Q1 2026.

• On a quarterly basis, EBT fell 112.64% year-over-year to -$453.8 million in Q1 2026; TTM through Mar 2026 was -$240.4 million, a 65.57% increase from a year earlier, with the FY2024 full-year figure at -$600.8 million, down 36.59% from the prior year.
• EBT retreated to -$453.8 million in Q1 2026 per RVMD's latest filing, from $766.4 million in the prior quarter.
• Across five years, EBT topped out at $766.4 million in Q4 2025 and bottomed at -$453.8 million in Q1 2026.
• The 5-year median for EBT is -$116.0 million (2024), against an average of -$102.6 million.
• Across the five-year window, EBT tumbled 184.64% in 2023 and soared 492.38% in 2025, its largest moves.
• Year by year, EBT stood at -$56.6 million in 2022, then tumbled by 184.64% to -$161.2 million in 2023, then slipped by 21.17% to -$195.3 million in 2024, then surged by 492.38% to $766.4 million in 2025, then sank by 159.21% to -$453.8 million in 2026.
• Per Business Quant, the three latest RVMD EBT figures stand at -$453.8 million (Q1 2026), $766.4 million (Q4 2025), and -$305.2 million (Q3 2025).